What Is PT-141 (Bremelanotide)?

From Melanotan II to Bremelanotide: Discovery and Structure

PT-141 (`Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH`) is a cyclic seven-amino-acid peptide originally synthesized during university and pharmaceutical research on alpha-melanocyte-stimulating hormone (α-MSH) analogs (StatPearls / NIH).

Researchers initially studied Melanotan II as a sunless tanning agent, but early human subjects reported pronounced central sexual arousal alongside pigmentary and autonomic effects. Structurally, PT-141 is the deaminated metabolite/derivative of Melanotan II, differing only at the C-terminus: where Melanotan II terminates in a carboxamide (`-NH2`), PT-141 terminates in a free carboxylic acid (`-OH`). Bremelanotide is an FDA-approved prescription medication; unapproved formulations are not interchangeable with the approved product.

How PT-141 Works: Central Melanocortin Signaling vs. PDE5 Inhibitors & Testosterone

To understand why bremelanotide attracted so much neuroendocrine research, it helps to contrast its central mechanism in the brain with peripheral vascular medications like sildenafil (Viagra) or tadalafil (Cialis) as well as endocrine hormone therapies (NIH PMC):

1. Non-Selective Melanocortin Receptor Agonism (MC1R, MC4R, MC3R)

Bremelanotide binds non-selectively to several G-protein-coupled melanocortin receptor subtypes in the following order of affinity: MC1R > MC4R > MC3R > MC5R (with negligible activity at MC2R, the adrenal ACTH receptor). While binding at peripheral MC1R on cutaneous melanocytes accounts for its pigment-darkening side effect, its therapeutic action in hypoactive sexual desire disorder is mediated by MC4R and MC3R neurons in the medial preoptic area (mPOA) and paraventricular nucleus (PVN) of the hypothalamus.

2. Presynaptic Dopamine Release in the Medial Preoptic Area

PT-141 is discussed as acting on central melanocortin pathways involved in sexual desire, rather than directly changing sex-hormone levels.

3. PT-141 vs. Testosterone Therapy

Readers frequently ask how PT-141 compares with testosterone replacement therapy (TRT). The two operate on completely different biological systems and timelines:

• Mechanism (Neurotransmitter vs. Steroid Hormone): Testosterone therapy replaces deficient endogenous androgen hormones, binding nuclear androgen receptors across muscle, bone, and brain tissue over weeks to months. PT-141 is a non-hormonal neuropeptide analog that acts acutely on central hypothalamic MC4R/dopamine pathways within hours and does not raise serum testosterone, estradiol, LH, or FSH.
• Clinical Comparison: Testosterone changes hormone levels, while PT-141 acts on central neural desire pathways. Personal prescribing and monitoring decisions require a licensed clinician.

Human Clinical Trial Evidence

Bremelanotide's 2019 FDA approval (NDA 210557) was supported by controlled human clinical trials evaluating premenopausal women with acquired, generalized hypoactive sexual desire disorder (PubMed). Across the clinical program, participants treated with bremelanotide experienced improvements in sexual desire and reductions in distress related to low sexual desire compared with placebo (U.S. FDA Approval Package).

Earlier clinical trials also evaluated bremelanotide in men with erectile dysfunction, though the FDA-approved indication for Vyleesi is specifically for premenopausal women with acquired, generalized HSDD.

FDA Safety Profile, Side Effects, and Contraindications

Because bremelanotide is an FDA-approved prescription medication, its adverse-event profile is documented in clinical trial data and official prescribing information:

• Nausea: Nausea is the most frequently reported side effect following administration, sometimes requiring anti-nausea support or leading some patients to discontinue treatment.
• Flushing, Headache & Local Site Reactions: Facial flushing, headache, and mild redness or irritation at the administration site are commonly reported transient effects.
• Transient Blood Pressure Elevation: Bremelanotide can cause a temporary increase in systolic and diastolic blood pressure accompanied by a mild reflex reduction in heart rate after administration, which is why cardiovascular screening is required before prescribing.
• Focal Hyperpigmentation: Because bremelanotide also activates cutaneous MC1R receptors on melanocytes, darkening of the skin on the face, gums (gingiva), and breasts has been reported, particularly with more frequent exposure, and pigment changes do not always completely resolve after stopping the medication.
• Pregnancy & Breastfeeding: Personal questions about bremelanotide and reproductive safety require the prescribing clinician and approved product information.

Prescription Vyleesi vs. Unregulated Research Vials

Because bremelanotide is an FDA-approved drug (Vyleesi), obtaining it for human medical treatment in the United States requires a clinical evaluation and a valid prescription from a licensed healthcare provider, dispensed through a licensed pharmacy. Unapproved lyophilized vials labeled "PT-141" sold online without a prescription bypass FDA manufacturing controls and carry documented risks of synthesis truncation impurities, residual trifluoroacetic acid (TFA), incorrect net peptide mass, and bacterial endotoxins. For a complete guide to U.S. regulatory rules and analytical testing standards, read Do I Need a Prescription?, Where Do I Buy Peptides?, and Top Peptide Sources (2026).

Scientific References and Further Reading

1. Bremelanotide — StatPearls, National Center for Biotechnology Information (NIH)
2. Bremelanotide for the treatment of hypoactive sexual desire disorder: a systematic review of randomized controlled trials (PubMed)
3. U.S. Food and Drug Administration — Drug Approval Package: Vyleesi (bremelanotide)
4. Melanocortin receptors and sexual function: mechanism of action and clinical implications (NIH PMC)